- Home
- OTLY vs DRTS Comparison
OTLY vs DRTS Comparison
Compare OTLY & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OTLY | DRTS |
|---|---|---|
| Founded | 1994 | 2015 |
| Country | Sweden | Israel |
| Employees | N/A | 125 |
| Industry | Packaged Foods | Medical/Dental Instruments |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 394.1M | 546.5M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | OTLY | DRTS |
|---|---|---|
| Price | $11.05 | $6.97 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $15.50 | $8.00 |
| AVG Volume (30 Days) | 67.0K | ★ 291.9K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $7.91 | N/A |
| Revenue Next Year | $5.50 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.25 | $2.30 |
| 52 Week High | $18.84 | $8.60 |
Technical Indicators
Market Signals| Indicator | OTLY | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 42.78 | 47.71 |
| Support Level | $10.71 | $6.57 |
| Resistance Level | $12.58 | $7.77 |
| Average True Range (ATR) | 0.49 | 0.50 |
| MACD | -0.14 | -0.14 |
| Stochastic Oscillator | 15.17 | 28.26 |
Price Performance
Historical ComparisonAbout OTLY Oatly Group AB
Oatly Group AB is engaged in the food and drinks industry. Some of its products include Oat Drink, Chilled Oat Drink, Oatgurt, Creamy Oat, and Icecreams, among others. It caters to Sweden, Germany, the United Kingdom, Netherlands, North America, Finland, and Other markets. The company generates revenue from the EMEA, Americas, and Asia regions, with the majority of revenue generated from the EMEA region.
About DRTS Alpha Tau Medical Ltd.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company derives maximum revenue from Israel.